Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 7NET 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 12Gastro-enteropancreatic neuroendocrine tumor 4Carcinoid Tumor 3Neoplasms 2Carcinoma, Islet Cell 2Adenoma, Islet Cell 2Vipoma 1Somatostatinoma 1Serotonin Syndrome 1Pancreatic Neuroendocrine Tumor G2 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Hepatocellular 1Carcinoma 1Acromegaly 1

Interventions

Everolimus 8lanreotide 3gallium Ga 68 dotatate 3Octreotide 3Nivolumab 3pasireotide 2lutetium Lu 177 dotatate 2cabozantinib 2Temozolomide 2Sunitinib 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2zimberelimab 1veliparib 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1ganitumab 1fosbretabulin 1epothilone B 1cixutumumab 1arginyllysine 1TKM-080301 1Sorafenib 1Serotonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoid Tumor × Octreotide × NET × Clear all
NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡